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Abstract: Aging is associated with remodeling of
the immune system, contributing to increased inci-
dence of infections, autoimmune diseases, and can-
cer among the elderly. Alterations in several signal
transduction pathways have been reported to play an
important role in immunosenescence. We show that
peripheral blood leukocytes obtained from old do-
nors (>65 years) have a significantly reduced expres-
sion of receptor for activated C kinase 1 (RACK-1), a
protein required for protein kinase C (PKC)- signal-
ing, as compared with young donors (<40 years),
both in males and females. The decline in RACK-1
immunoboth in reactivity was age-related (Spearman
correlation, r–0.278, P0.012). All leukocyte
subpopulations, namely lympho-monocytes, granulo-
cytes, and B and T cells, showed a similar defect. We
also observed a direct correlation between circulat-
ing dehydroepiandrosterone (DHEA) and RACK-1
expression in leukocytes (Spearman correlation,
r0.388, P0.001). Furthermore, in vitro treat-
ment with DHEA resulted in increased RACK-1 ex-
pression in leukocytes and lymphocyte proliferation,
confirming the role of this hormone in the modula-
tion of its expression and immune functions. A rele-
vant consequence of RACK-1-reduced expression
was the observation that release of tumor necrosis
factor  following lipopolysaccharide challenge and
mitogen-induced lymphocye proliferation, which in-
volves PKC- activation, was significantly reduced in
elderly subjects. Overall, our findings contribute to
the understanding of the complex process of immu-
nosenescence and identify age-related loss in immu-
nological responses as partially associated with de-
creased RACK-1 expression. J. Leukoc. Biol. 77:
247–256; 2005.
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INTRODUCTION
The immune system is less able to cope with infectious disease
during aging than earlier in life. Age-related changes in the
immune system contribute to the increased incidence and
severity of infections and possibly incidence of cancer among
the elderly [1, 2]. Many studies have established that age-
associated immune decline is characterized by a decrease in
humoral and cellular responses [3]. Many factors contribute to
immunosenescence, including stem-cell defects, thymus invo-
lution, aging of resting immune cells, replicative senescence of
clonally expanding cells as a result of erosion of telomere ends,
defects in antigen-presenting cells, dysfunction in several sig-
nal transduction pathways, and dysregulation of the cytokine
network [4–6].
We have recently demonstrated [7, 8] that the age-associ-
ated decline in rat immune function reflects an impaired pro-
tein kinase C (PKC) signal-transduction pathway and in par-
ticular, is related to a defective PKC-anchoring system. PKC is
a family of at least 12 phospholipid-dependent, serine-threo-
nine kinases involved in the signal transduction of hormones,
neurotransmitters, and cytokines [9]. It mediates essential cel-
lular signals required for activation, proliferation, differentia-
tion, and survival of immune cells [10]. Activation of PKC
results in redistribution (translocation) of the enzyme from the
cytosol to membrane compartments for exerting its function [9].
This process is believed to be mediated by a family of proteins,
receptors for activated C kinase (RACKs) [11]. One such
protein, RACK-1, a 36-kDa protein cloned from rat brain, is
the best-characterized member of the RACK family; it prefer-
entially interacts with PKC-. RACK-1 modulates PKC activ-
ity by stabilizing its active conformation [12, 13]. Other pro-
teins, such as rat synaptic vesicle-specific p65 protein, phos-
pholipase C (PLC), PLC-A2, and annexin, can bind to
RACK-1 via a sequence similar to the C2 domain of PKC,
suggesting that RACK-1 may play a critical role in anchoring
a range of proteins to the membrane and may integrate signal-
ing pathways with different physiological functions [14]. The
cDNA encoding RACK-1-like proteins has been identified
from numerous organisms [15]. The expression of RACK-1
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protein is variable in different organisms or different develop-
mental stages. In mouse, RACK-1 is highly expressed in
embryonic brain, but its expression decreases variably in dif-
ferent areas of the brain after postnatal development [16]. In
rats, we demonstrated a development-associated increase in
the expression of PCK-II and RACK-1, which correlated with
the maturation of alveolar macrophage functional responses in
rats at 2, 4, and 12 weeks of age [17]. By the age of 12 weeks,
young adult rats possess fully matured alveolar macrophages
with respect to their ability to respond to stimuli.
Concerning aging of the immune system, we have shown that
a deficit in RACK-1, in the absence of differences in the
expression of total PKC isoforms, underlies defective PKC
activation and functional immune impairment in aged rats [7,
8]. Defective PKC activation with aging has also been reported
by several authors in human monocytes [18, 19] and in human
T lymphocytes [20, 21], and 50% of elderly subjects has
significant reduction in PKC activity in B cells [22]. Age-
related impairment of the translocation of PKC is likely to
underlie downstream defects in the activation of immune re-
sponses in vitro, as diminished generation of cytotoxic effec-
tors, lower production of some cytokines, and reduced prolif-
erative responses, and in vivo, as diminished response to
vaccination and increased susceptibility to infections. It is now
emerging that individual isoforms of PKC may exert specific
functions in maintaining proper lymphocyte activation and
tolerance. Mice homozygous for a target disruption of the gene
encoding the PKC-I and PKC-II isoforms develop an im-
munodeficiency characterized by impaired humoral immune
response [23]. Similarly, mature T lymphocytes in PKC--
deficient mice exhibit defects in T cell antigen receptor-in-
duced proliferation and reduced T-dependent responses [24].
In contrast, mice deficient in the  isoform of PKC exhibit B
cell hyperactivation, which leads to autoimmunity [25], dem-
onstrating the critical and complex role for specific PKC iso-
forms in B and T cells functions.
We previously demonstrated that dehydroepiandrosterone
(DHEA) treatment restores the age-decreased level of RACK-1
and immune deficits in rats, indicating that the age-related loss
in immunological responses, linked to defective pathways of
signal transduction, are under hormonal control and can be
restored by appropriate replacement therapy [8]. In human,
DHEA and its sulfate (DHEAS), the most abundantly secreted
adrenal steroids, are known to increase throughout childhood
and puberty and then to decrease in old age [26]. Following the
peak by the third decade of life, its level declines steadily by
2% per year in males and females. It is important to mention
that rodent adrenals lack the enzyme necessary to synthesize
C-19 steroids and therefore, do not contribute to plasma levels
of androstenedione and DHEA [27]. The average plasma level
of DHEA in rodent is 0.6 ng/ml, at least 10 times less than the
average concentration in men [28]. Nevertheless, a decrease
with age of DHEAS in rodents can be observed as well: we
observed in 21-month-old rats a 50% reduction in plasma level
of DHEAS, a stable marker of circulating DHEA levels [8].
Reduced secretion of DHEA during aging has been related to
a series of age-associated conditions [29, 30], including several
lines of evidence, which indicate that DHEA and its metabo-
lites are potent regulators of the immune response [31, 32].
Substantial data from animal studies have demonstrated a
stimulatory effect of DHEA on immune function. For example,
we demonstrated in vitro and in vivo that DHEA can restore
lipopolysaccharide (LPS)-induced tumor necrosis factor 
(TNF-) production in macrophages and in vivo mitogen-
induced splenocyte proliferation [8]; May et al. [33] demon-
strated that DHEA administration reversed corticosteroid and
stress-induced inhibition of immune function, Loria et al. [34]
showed that its administration has a protective effect against
systemic Coxsackie virus and Herpes simplex type 2 enceph-
alitis, and Daynes et al. [35] found that it can enhance inter-
leukin (IL)-2 production by activated murine T cells. However,
too little is known about the effects of DHEA supplementation
on the human immune system, and it is still premature to relate
these findings to routine clinical applications. In a small clin-
ical trial, it has been demonstrated that orally administered
DHEA (50 mg/daily) to age-advanced men with low serum
DHEAS safely activated several immune functions within 2–20
weeks of treatment, including B and T cells mitogenic response
and phytohemagglutinin (PHA)-induced IL-2 production, sug-
gesting potential therapeutic benefits of DHEA supplementa-
tion in immunodeficient states [36].
Given the increasing proportion of elderly people worldwide,
a better understanding of the causes and mechanisms of im-
munosenescence is crucial to identify whether prevention
might be beneficial to enhance quality of life and to reduce the
cost of medical care in old age. We therefore investigated
RACK-1 expression in human peripheral blood leukocytes and
the role of DHEA in an age-associated decrease in RACK-1.
Accordingly, the present study was designed to determine if an
age-related decline in RACK-1 expression was present and
whether it would be correlated with circulating DHEA and
paralleled by functional significance in humans.
MATERIALS AND METHODS
Chemicals
LPS from Escherichia coli serotype 0127:B8 and DHEA were obtained from
Sigma Chemical Co. (St. Louis, MO), antibodies against RACK-1 from Trans-
duction Laboratories (Affinity, Nottingham, UK), and anti-human -actin from
Sigma Chemical Co. Electrophoresis reagents were from Bio-Rad (Richmond,
CA). All reagents were purchased at the highest purity available.
Study protocol
In this study, a total of 84 subjects living in the same geographical area of
Northern Italy were recruited. These subjects included 20 elderly subject (age
71.80.8 years, range 65–78;  65 years) and 64 subjects (age 39.71.4
years, range 23–63; 65 years). The 65 years group was further divided in
two subgroups: a young adult 40 years (n	36, meanSEM, 32.21.0 years)
and adult 41–64 years old (n	 20, meanSEM, 50.51.6 years). All subjects
signed an informed consent and were selected according to the guidelines of
the Italian Health authorities and to the Declaration of Helsinki principles.
Criteria for exclusion were abnormal laboratory values, medication known to
affect the immune system, i.e., steroids and nonsteroideal, anti-inflammatory
drugs, or patients suffering from malignancies, inflammations, and infections.
Blood samples (5 ml) were taken by venous puncture with sodium citrate 0.5
M as anticoagulant. Sodium citrate was chosen instead of heparin or EDTA as
anticoagulant, as functional assays were performed using the whole blood
assay, heparin may be contaminated with endotoxin, and EDTA interferes with
cell activation.
248 Journal of Leukocyte Biology Volume 77, February 2005 http://www.jleukbio.org
To investigate the in vitro effect of DHEA on RACK-1 expression, whole
blood was washed three times with sterile phosphate-buffered saline, and the
packed cells were reconstituted to the original volume with RPMI without
phenol red (Sigma Chemical Co.) supplemented with 10% charcoal-stripped,
heat-inactivated calf serum (Sigma Chemical Co.). Diluted, washed blood
(1:10) was then incubated for 24 h in the presence or absence of DHEA (15
ng/ml) or dimethyl sulfoxide as vehicle control. Cell homogenates were pre-
pared for Western blot analysis as described below, and for mitogen-stimulated
proliferation or cytokine release, diluted whole blood was then incubated in the
presence or absence of PHA 1.2 
g/ml or 10 ng/ml phorbol myristate acetate
(PMA) plus 100 ng/ml ionomycin or LPS (1 
g/ml) as described below.
To investigate the role of PKC- in LPS-induced cytokine production,
diluted whole blood was cultured for 2 h in the presence or absence of a
selective cell-permeable inhibitor of PKC- (PKC- pseudosubstrate, cat. no.
1792, Tocris, Avonmouth, UK). Then, LPS 0.1 
g/ml was added for 24 h.
Cytokine release in conditioned media was evaluated by commercially avail-
able enzyme-linked immunosorbent assay (ELISA) kits. The concentration of
inhibitor used was not cytotoxic, as assessed by lactate dehydrogenase leakage
in conditioned media (data not shown).
Animals
Young (3 months) and old (18 months) Sprague-Dawley male rats were pur-
chased from Charles River (Calco, Italy). All animal care procedures were in
accordance with the Italian Guidelines for Care and Use of Experimental
Animals. Blood samples were taken by cardiac puncture with sodium citrate
0.5 M as anticoagulant.
Western blot analysis
For RACK-1 and -actin expression in leukocytes, 1.0 ml blood was treated
with ammonium chloride to remove red cells, and then the remaining leuko-
cytes were lysed in 100 
l homogenization buffer (50 mM Tris, 150 mM NaCl,
5 mM EDTA, pH 7.5, 0.5% Triton X-100, 50 
M phenylmethylsulfonyl
fluoride, 2 
g/mL aprotinin, 1 
g/mL pepstatin, and 1 
g/mL leupeptin) and
denatured for 10 min at 100°C [37]. For enrichment in lympho-monocytes,
these cells were separated from granulocytes using a density gradient. Blood
was diluted (1:3) with Hanks’ balanced saline solution and layered on top of a
tube containing lymphocyte separation medium (Gibco-BRL, Paisley, UK).
After centrifugation at 2400 rpm for 30 min, the lympho-monocytes were
recovered at the interface of the medium and Ficoll, centrifuged and lysed in
50 
l homogenization buffer, and the pellet, containing red cells and granu-
locytes, was treated with ammonium chloride to remove red cells, and then the
remaining granulocytes were lysed in 50 
l homogenization buffer. B and T
lymphocytes were enriched using RosetteSep™ from StemCell Technologies
Inc. (Vancouver, BC, Canada) from whole blood obtained from young and old
donors (n	4). The RosetteSep™ consists of a cocktail of patented, reagent-
complexed, tetrameric antibody. The cocktail targets a variety of unwanted
cells and cross-links them to red blood cells present in the sample forming
rosettes. The desiderated (unrosetted) cells are then collected as a centrifuged
population from a Ficoll gradient. With this method, a 97% enrichment in
CD3 cells and a 81% enrichment in CD19 are obtained. After separation,
the enriched populations were lysed in 50 
l homogenization buffer and
prepared for Western blot analysis as described above. The protein content of
the cell lysate was measured using a commercial kit (Bio-Rad). The cell
proteins (30 
g) were electrophoresed into a 12% sodium dodecyl sulfate-
polyacrylamide gel under reducing conditions. The proteins were then trans-
ferred to a polyvinylidene difluoride membrane (Amersham, Little Chalfont,
UK). The different proteins were visualized using RACK-1 (1:2500) and
-actin (1:5000) primary antibodies and developed using enhanced chemilu-
minescence (Amersham). The image of the immunoblotting was acquired with
a Nikon charged-coupled device video camera module. The optical density of
the bands was calculated and analyzed by means of the Image 1.47 program for
digital image processing (Wayne Rasband, Research Service Branch, National
Institutes of Mental Health, National Institutes of Health, Bethesda, MD).
Assay for DHEA
The levels of DHEA in human blood were determined by a commercially
available enzyme immunoassay (Assay Design, Inc., Ann Arbor, MI) following
the supplier’s instructions. The limit of detection of the assay was 2.9 pg/ml.
Results are expressed as ng/ml.
Lymphocyte subpopulations
Peripheral blood (50 
l) was stained with appropriate concentration of fluo-
rescein- or phycoerythrin-conjugated monoclonal antibodies (mAb) against
CD3, CD4, CD8, CD19, CD25, and CD56/CD16 (Becton Dickinson, San Jose,
CA) following the supplier’s instructions. Flow cytometric analysis was per-
formed in accordance with standard procedures on FACScan flow cytometry.
Results are expressed as percentage or as absolute number of positive cells.
Mitogen-stimulated proliferation assay
Functional assays were performed using whole blood, added with sodium
citrate as anticoagulants. Blood was diluted 1:10 with cell-culture medium
RPMI 1640 (Sigma Chemical Co.) containing 2 mM L-glutamine, 0.1 mg/ml
streptomycin, 100 IU/ml penicillin, as described previously [38]. Microcul-
tures for the evaluation of mitotic response were set up in triplicates with 150

l diluted whole blood in 96-well plates in medium alone or in the presence
of the following mitogenic stimuli: anti-CD3 mAb at a final concentration of 25
ng/ml (Sigma Chemical Co.), PHA (Invitrogen, Paisley, UK) 1.2 
g/ml and 10
ng/ml PMA (Sigma Chemical Co.), plus 100 ng/ml ionomycin (Sigma Chemical
Co.). Cells were cultured for 96 h at 37°C in a humidified 5% CO2 incubator
and were pulsed during the final 18 h with 1 
Ci/well 3H-thymidine (Amer-
sham). Cells were harvested using a cell harvester (Dynatech, PBI, Milan,
Italy), and the uptake of 3H-thymidine was measured in a scintillation counter
(Packard, Meriden, CO). Results are expressed as stimulation index (S.I.),
calculated as follows: S.I. 	 cpm mitogen/cpm medium alone.
Cytokine production
For the evaluation of cytokine production, cultures were set up in open 12 
75 polypropilene reaction tubes (Falcon, Oxnard, CA) containing 1 ml 1:10
diluted whole blood in medium alone or in the presence of LPS at a final
concentration of 1 
g/ml. Cells were incubated for 24 h at 37°C in a humidified
5% CO2 incubator. Cell-free supernatants obtained by centrifugation at 1200
rpm for 5 min were stored at –20°C until measurement. Cytokine production
was assessed by ELISA using a commercially available kit (PharMingen, San
Diego, CA). Results are expressed in pg/m for TNF- and ng/ml for IL-8.
Statistical analysis
Data are expressed as mean  SEM. Statistical analysis was performed using
GraphPad InStat Version 3.0a for Macintosh (GraphPad Software, San Diego,
CA). Statistical differences were determined using the unpaired t-test or a
multiple comparison test as indicated in the legends. Spearman correlation was
used to analyze the correlation among RACK-1, age, and DHEA. Effects were
designated significant if P  0.05.
RESULTS
Aging is associated with a progressive decline in
RACK-1 expression in human leukocytes
We have previously demonstrated that aging is associated with
a progressive decrease in RACK-1 expression in rat macro-
phages and splenocytes obtained from outbred rats [7, 8] and
that this defect correlates with a decrease in PKC-dependent
immune functions. The purpose of this study was to investigate
whether a similar defect was also associated with human im-
munosenescence. Before starting the human study, RACK-1
immunoreactivity was evaluated in peripheral blood leukocytes
obtained from young (3 months) and old (18 months) rats. To
control protein loading and to normalize RACK-1 expression,
we evaluated -actin immunoreactivity. As shown in Figure
1A, a statistically significant decrease in RACK-1 expression
was observed, indicating that in rats, the previously identified
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defect in macrophages and splenocytes is also detectable in
blood. RACK-1 immunoreactivity was then evaluated by West-
ern blot analysis of human peripheral blood leukocyte homog-
enate, obtained from healthy old (65 years) and young adult
( 40 years) donors. As shown in Figure 1B, a significant
decrease in RACK-1 expression was also observed in leuko-
cytes obtained from old individuals in comparison with young
donors with a reduction of 37.5  2.0% of RACK-1 immuno-
reactivity (P	0.0005). The decline in RACK-1 immunoreac-
tivity with age was observed in leukocytes obtained from fe-
male and male donors without significant differences among
genders (Table 1).
We then evaluated the correlation between the decline in
RACK-1 immunoreactivity and aging, including the data of
RACK-1 expression in blood leukocytes obtained from all
donors enrolled in the study. We found that RACK-1 expres-
sion progressively declines with age as shown in Figure 2,
reporting the levels of RACK-1 plotted against the respective
ages (Spearman correlation, r	–0.278, and P	0.012).
As the antibody against RACK-1 used lacks adequate spec-
ificity, its use for flow cytofluorimetric analysis is precluded.
Thus, to investigate the contribution of leukocyte subpopula-
tions in RACK-1 immunoreactivity, different strategies were
followed. First, lympho-monocytes were separated from gran-
ulocytes using a density gradient, and second, B and T lym-
phocytes were enriched using RosetteSepTM from blood ob-
tained from young and old donors (n	4). As reported in
Figure 3, a statistically significant reduction with aging in
RACK-1 expression was observed in all leukocyte subpopula-
tions investigated, indicating that the decrease in RACK-1
expression with aging reflects a defect common to all leuko-
cytes. Thus, the results obtained from whole blood, even if
crude, are representative of a defect associated with immu-
nosenescence.
Serum levels of DHEA correlate with RACK-1
expression
We previously demonstrated that age-related loss in functional
responses linked to PKC signal transduction defective pathway
is partially under hormonal control and can be restored in rats
by DHEA supplementation [8]. We speculated that a hormonal
change (i.e., decrease in DHEA) in the cell environment as-
sociated with aging may be responsible for the loss in RACK-1
expression.
We observed (Fig. 4) that aging, as expected, was signifi-
cantly correlated with a progressive decline in the plasma level
Fig. 1. Decreased RACK-1 immunoreactivity in peripheral blood leukocytes
obtained from young and old individuals. (Left panels) Reported, representa-
tive Western blot analysis of RACK-1 and as control for protein loading,
-actin immunoreactivity in peripheral blood leukocyte homogenate obtained
from young (3 months) and old (18 months) male rats (A) and human healthy
donors 40 years old and 65 years old (B). (Right panels) The histograms
show the quantification of RACK-1/-actin ratio by densitometric analysis.
Each value represents the mean  SEM of five rats (A) and 36 donors for the
group 40 years and 20 for the group 65 years (B). Statistical analysis has
been performed by unpaired t-test. The P value is reported in the figure.
TABLE 1. RACK-1 Immunoreactivity in Leukocytes Obtained
from Female and Male Donors
Donors RACK-1/-actin ratio
Young females, n 	 11 (age 35.11.8) 0.63  0.06
Young males, n 	 25 (age 31.01.2) 0.54  0.04
Old females, n  7 (age 72.71.0) 0.36  0.06*
Old males, n 	 13 (age 70.71.4) 0.34  0.07*
Values are mean  SEM. Column two reports the ratio RACK-1/-actin in
leukocyte homogenates individually obtained and analyzed from young (40
years) and old (65 years) female and male healthy donors. Statistical analysis
was performed by Bonferroni multiple comparison test. * P  0.05 versus
young donors.
Fig. 2. Correlation between age and RACK-1/-actin ratio in human periph-
eral blood leukocytes. Correlation analysis of data was performed by Spearman
correlation. The correlation coefficient, r, and P values are reported in the
figure. Each dot represents a donor (n	84).
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of DHEA (Spearman correlation, r	0.468, P	0.001). It is
interesting that in spite of a relatively low correlation coeffi-
cient, we observed a statistically significant correlation be-
tween RACK-1 expression in leukocytes and plasma level of
DHEA (Spearman correlation, r	0.388, P	0.001; Fig. 5). To
further support the role of DHEA on RACK-1 expression, the
effect of a physiologically relevant concentration of DHEA (15
ng/ml) was evaluated in washed whole blood obtained from six
donors of different ages. As shown in Figure 6A, treatment
with DHEA for 24 h resulted in an increase in RACK-1
immunoreactivity in all donors tested compared with the ex-
pression of RACK-1 in vehicle-treated blood. In all tested
samples, the expression of RACK-1 at least doubled (range
from 102% to 350%) following DHEA treatment, indepen-
dently from the age of the donor. In another study, washed
whole blood obtained from old individuals was treated in the
presence or absence of DHEA for 24 h and then stimulated
with PHA and phorbol ester plus ionomycin to assess lympho-
cyte proliferation. As shown in Figure 6B, in vitro treatment
with DHEA resulted in increased mitogen-induced cell prolif-
eration in all subjects (range from 26% to 176% for PHA;
from 40% to 114% for phorbol ester plus ionomycin), con-
firming the immuno-stimulatory properties of DHEA. These in
vitro data are consistent with data obtained by Khorram et al.
[36] in elderly men, who reported that in vivo supplementation
with DHEA resulted in a restoration of mitogen-induced lym-
phocyte proliferation. The addition of the selective inhibitor of
PKC- significantly reduced PHA and phorbol ester plus
ionomycin-induced cell proliferation and prevented DHEA
increased proliferation. From a 70-year-old donor, the S.I. after
PHA was 80.8 in control cells, it was 103.0 in the presence of
DHEA, and it was reduced to 48.4 in control cells treated with
the PKC- inhibitor and 80.5 in cells treated with DHEA and
the PKC- inhibitor. Similarly, after PMA plus ionomycin, the
S.I. was 82.7 in control cells, 97.2 in the presence of DHEA,
55.7 in control cells treated with the PKC- inhibitor, and 67.9
in cells treated with DHEA and the PKC- inhibitor, indicat-
ing that PKC- is indeed involved in mitogen-induced cell
proliferation.
Relative to TNF- production, we have previously demon-
strated that DHEA can restore age-associated, defective
TNF- production in response to LPS in rat macrophages [8].
In humans, the experiments in vitro are complicated by the fact
that to perform hormonal treatment, we need to wash away the
autologous serum, and cells have to be cultured in charcoal-
stripped serum. In these conditions, cells are probably lacking
the presence of essential elements for an optimal response to
LPS (i.e., the LPS-binding protein). An example of such effect
can be given by some details of an experiment performed on
the same sample of blood from an old donor. When such
sample is simply diluted, and cells are exposed to their serum,
the TNF- production following LPS is 325 pg/ml. When the
same sample is washed and diluted to the same final volume in
the presence of charcoal-stripped serum, the TNF- produc-
Fig. 3. RACK-1/-actin immunoreactivity in leukocyte subpopulation. Cell
homogenates from lympho-monocytes, granulocytes, and T and B cells sepa-
rated from blood obtained from young (40 years, n	4) and old donors (65
years, n	4) were analyzed by Western blot analysis for RACK-1 and -actin
immunoreactivity. Each value represents the mean  SEM of four donors.
Statistical analysis was performed by unpaired t-test, and *, P  0.05, versus
RACK-1/-actin ratio in young donors.
Fig. 4. Correlation between age and plasma level of DHEA in the humans
enrolled into the study. Correlation analysis of data was performed by Spear-
man correlation. The correlation coefficient, r, and P values are reported in the
figure. Each dot represents a donor (n	84).
Fig. 5. Age-related correlation between plasma level of DHEA and RACK-
1/-actin ratio in human peripheral blood leukocytes. Correlation analysis of
data was performed by Spearman correlation. The correlation coefficient, r, and
P values are reported in the figure.
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tion following LPS drops to 73 pg/ml. For the same sample,
DHEA treatment (made in charcoal-stripped serum) brings
TNF- production after LPS to 110 pg/ml. In the presence of
these limitations, we nevertheless observed that treatment with
DHEA (15 ng/ml) on washed whole blood from three young
donors and two old donors produced a significant increase in
LPS-induced TNF- release, ranging from 37% to 53% in
young donors and from 50% to 86% in old donors. Also in
this case, the addition of the selective inhibitor of PKC-
prevented the stimulatory effect of DHEA on LPS-induced
TNF- release: DHEA induced a 58  23% increase in
TNF- release, which was reduced to 3  28% in the
presence of the PKC- inhibitor, further supporting the link
between DHEA/RACK-1 and PKC-.
Decreased functional response in leukocytes of
old donors
Aging is associated with a functional decline of the immune
system [39]. We initially performed assays on whole blood
from young and old donors (n	6) to study proliferative
responses to anti-CD3 antibody, PHA, and phorbol ester
plus ionomycin to assess congruity of our aged population
with literature data. An extremely significant reduction in
mitogen-induced lymphocyte proliferation was observed in
aged donors in comparison with young donors, consistent
with literature data (Table 2) [5, 6, 40].
The decrease in lymphocyte proliferation is unlikely to be a
result of change in the absolute number or percentage of B and
T cells. Fluorescence-activated cell sorter analysis performed
on blood from young and old subjects showed 73.8  1.8%
versus 73.2  1.7% in CD3/CD45 cells in young versus old
donors (absolute number 127191.8 vs. 1421203 cells/
l)
and 10.6  0.8% versus 11.7  1.4% in CD19/CD45 cells
(absolute number 185.417.7 vs. 27837.2 cells/
l). This is
consistent with Stulnig et al. [41], who reported that the num-
ber and relative percentage of lymphocytes CD3 and CD19
or monocytes were similar in healthy young and old subjects.
In rats, we have shown that aging was associated with a
progressive decline in the ability of alveolar macrophage to
release TNF- in response to LPS as a result of reduced
RACK-1 expression [7]. In our population, we found that
stimulation with LPS in whole blood assays resulted in signif-
Fig. 6. DHEA up-regulated in vitro RACK-1 ex-
pression in peripheral blood leukocytes and stim-
ulated mitogen-induced cell proliferation. (A, In-
set) A representative Western blot analysis of
RACK-1, and as control for protein loading, -ac-
tin immunoreactivity in peripheral blood leukocyte
homogenate obtained from a 70-year-old female
donor is reported following 24 h incubation in the
presence or absence of DHEA (15 ng/ml). Data are
reported that were obtained from six healthy do-
nors. F, Female; M, male; y, years. (B) Mitogen-
induced proliferative response. Washed whole
blood obtained from old donors was treated for 24 h
in the presence or absence of DHEA (15 ng/ml);
then, PHA 1.2 
g/ml or 10 ng/ml PMA plus 100
ng/ml ionomycin was added. Results are expressed
as S.I.
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icantly reduced levels of TNF- released by cells from old
donors as compared with young donors, as assessed by a
specific ELISA (Fig. 7A). The decrease in LPS-induced
TNF- release was age-related, as a progressive decline was
observed in the middle-aged donors (41–64 years old). The
spontaneous release of this cytokine was below the limit of
detection in all groups. In contrast, the release of IL-8, another
proinflammatory cytokine, was not affected by aging. A similar
release in spontaneous and LPS-stimulated IL-8 release was
observed in all donors (Fig. 7B). This observation may be a
result of a differential involvement of PKC- in LPS-induced
TNF- and IL-8 production. As shown in Table 3, treatment
with a selective inhibitor of PKC- in human whole blood
significantly reduced LPS-induced TNF- (from 732277
pg/ml to 263117 pg/ml), and no change in IL-8 production
was observed, indicating that PKC- isoform is involved in the
pathway leading to TNF- production but not in LPS-induced
IL-8 production. This effect was observed in young and old
donors. The fact that the selective inhibitor of PKC- did not
completely abrogate LPS-induced TNF- production may sug-
gest that the PKC- signaling pathway does not control TNF-
production exclusively.
DISCUSSION
Altogether, the data suggest a cascade of events leading to an
age-associated, defective activity of PKC signal transduction
machinery involved in the regulation of immune functions. In
particular, in spite of a large, interindividual variability, a
positive correlation between plasma level of DHEA and
RACK-1 immunoreactivity was found, suggesting an important
role of this hormone in maintaining RACK-1 expression and
TABLE 2. Proliferative Response to Mitogens in Peripheral Blood
Leukocytes Obtained from Young and Old Donors
Donors S.I.
Young, n 	 6 (age 29.02.6):
Anti-CD3 25 ng/ml 104.2  21.2
PHA 1.2 
g/ml 396.8  56.8
PMA 10 ng/ml plus 100 ng/ml ionomycin 267.3  73.0
Old, n 	 7 (age 77.23.2):
Anti-CD3 25 ng/ml 3.5  1.0**
PHA 1.2 
g/ml 42.4  9.2**
PMA 10 ng/ml plus 100 ng/ml ionomycin 22.1  6.0**
Diluted whole blood from donors of different ages was incubated for 96 h in
medium alone or with optimal concentrations of different mitogenic stimuli.
Cell proliferation was evaluated by 3H-thymidine incorporation. Results are
expressed as S.I. Background level of counts in unstimulated cells did not
differ significantly between young and old donors (340116 cpm, minimum
126, median 214, maximum 1016 for young donors and 455106 cpm,
minimum 207, median 368, maximum 817 for old donors). Values are
means  SEM. Statistical analysis was performed by unpaired t-test. ** P 
0.01 versus young donors.
Fig. 7. Decreased TNF- release in LPS-stimulated whole blood obtained from old donors. Whole blood obtained from healthy donors of different ages was diluted
1:10 and incubated for 24 h in the presence or absence of LPS (1000 ng/ml). TNF- (A) and IL-8 (B) release was assessed by specific ELISA. Each value represents
the mean  SEM, n 	 number of donors reported in the figure. Statistical analysis was performed by Tukey multiple comparison test, and **, P  0.01, versus
spontaneous release (0 LPS) and §, P  0.05, and §§, P  0.01, versus 40-year group.
TABLE 3. Effect of a Selective, Cell-Permeable Inhibitor of
PKC- (PKC- Pseudosubstrate) on LPS-Induced TNF-
and IL-8 Release from Human Leukocytes
Treatment TNF- (pg/ml) IL-8 (pg/ml)
Control 2  3 168  186
PKC- inhibitor 5 
M 3  5 97  68
LPS 0.1 
g/ml 732  277** 6696  790**
PKC- inhibitor  LPS 263  117**,§§
6450  797**
Diluted whole blood obtained from four young donors was incubated for 2 h
in the presence or absence of the PKC- inhibitor, and then LPS was added
where indicated for 24 h. Values are means  SD. Statistical analysis was
performed by Tukey-Kramer multiple comparison test. ** P  0.01 versus
relative control and §§ P  0.01 versus LPS-treated cells.
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PKC--mediated immune activation in human leukocytes. The
decreased DHEA levels appear to drive a defect in leukocyte
expression of RACK-1, in turn, leading to impaired PKC
functions and consequent defective, functional, immunological
responses. If true, the understanding of such mechanism of
immunoregulation in the aged immune system may lead to
effective treatment for age-related human diseases in the fu-
ture.
In addition, our previous research in experimental animals
demonstrated that not only the immune system but also the
nervous system responded to DHEA supplementation with
increased RACK-1 expression [42, 43], supporting a general-
ized role of this hormone in maintaining PKC-dependent func-
tional responses. It is indeed emerging that the defect in PKC
activation with aging reflects changes in signals that recruit
PKC to the membrane rather than alterations in enzyme levels
or intrinsic functional capacity [20, 44].
The mechanism of action of DHEA is still controversial, and
further studies are necessary to address this point. At present,
we cannot directly establish whether DHEA or its metabolites
selectively increase the transcription of RACK-1 through a
direct interaction with the androgen receptor or other down-
stream transcription factors or by activation of a specific
plasma membrane receptor, whose physiological functions
have not been characterized yet [44, 45]. With the use of
flutamide, an androgen receptor antagonist, we could demon-
strate in rat macrophages that DHEA-induced RACK-1 ex-
pression was prevented, suggesting that DHEA or more likely,
its metabolites act through the androgen receptor. However, in
the 5-flanking region, at least within 800 bp upstream of the
putative promoter region of the porcine RACK-1 gene, no
androgen receptor transcriptional binding sites have been de-
scribed [46]. It has been demonstrated recently that nuclear
factor (NF)-B regulates the mouse RACK-1 gene expression,
and specific inhibitors of NF-B activation decrease RACK-1
expression in PC12 cells [47]. In preliminary experiments, we
found that treatment of alveolar macrophages obtained from old
rats with DHEA (3 ng/ml) for 30 min resulted in p65 nuclear
translocation and inhibitor of B degradation, indicating
NF-B activation, which in turn, may account for DHEA-
induced RACK-1 neosynthesis, a putative mechanism that
awaits further characterization.
A speculation can be made that hormonal changes in the cell
environment associated with aging, in particular, the age-
related decline in the levels of DHEA, are likely to contribute
to the loss in RACK-1 expression in leukocytes. In rats, a
support to such speculation may be derived from the data that
indicate that newly generated cells in the bone marrow of old
rats have a similar level of RACK-1 as bone marrow cells
isolated from young rats. It is during the maturation, differen-
tiation, and distribution in blood and secondary lymphoid
organs that immune cells, influenced by the hormonal milieu,
start to exhibit a reduction in the levels of RACK-1 in aged rats
(data not shown). The reduction with aging in RACK-1 expres-
sion was observed in all leukocyte subpopulations investigated,
indicating that it may reflect a defect common to all leukocytes.
Thus, the results reported from whole blood, even if crude, are
indeed representative of a defect associated with immunose-
nescence. It is also possible that cells may express an aging-
related change in the hormonal sensitivity, although in such
case, it would be more difficult to explain the differences
among young and old individuals as well as the response of the
cells from aged donors to the hormone. Certainly, the defect
cannot be ascribed to gross changes in the number and subtype
composition of the leukocyte population as shown here and
consistent with the literature [41].
Using the whole blood assay, we found a decrease with
aging in the proliferative response to mitogens and a de-
crease in LPS-induced TNF- release in the old donors, and
no changes in LPS-induced or spontaneous IL-8 production
were detected. The whole blood assay was used, as it
requires less blood, cells are maintained in their natural
environment, and the risk of loss of minor lymphocyte
subsets through density gradient is eliminated. The de-
crease in the proliferative responses is consistent with data
published in the literature [6], and conflicting results have
been published concerning the effect of aging on proinflam-
matory cytokine production, with data reporting increase
[48, 49], no change, or decrease production [50]. This is
likely to be a result of different methodologies used (i.e.,
whole blood vs. purified cells), incubation time, stimuli, and
different leukocyte subset contribution among others. In-
deed, after stimulation of whole blood samples from healthy
elderly with LPS [51], IL-1 and IL-6 secretion were signif-
icantly elevated, but stimulation of their peripheral blood
mononuclear cells showed lower amounts of cytokines com-
pared with peripheral blood mononuclear cells of healthy
young donors.
Overall, cytokines are essential for proper antigen presen-
tation, activation of lymphocytes, and elimination of invading
microorganisms; thus, the alteration of the cytokine network is
believed to play a role in the remodeling of the immune system
in old age [52]. In this paper, we measured LPS-induced
TNF- and IL-8 production. TNF- is one of the major cyto-
kines produced during an infection. A decrease in the ability of
cells to produce this cytokine is likely to contribute to in-
creased susceptibility to infections. IL-8 is an inflammatory
cytokine, which functions mainly as a neutrophil chemoattrac-
tant, and activating factor.
In whole blood, most cell types are able to produce many
cytokines. B and T cells and monocytes are the main producers
of TNF-, and IL-8 production is mainly a result of neutro-
phils, although also monocytes and B and T cells can produce
it. Using the selective, cell-permeable inhibitor of PKC-, the
specific kinase isoform interacting with RACK-1, we could
demonstrate that only LPS-induced TNF- release could be
significantly modulated by the PKC- inhibitor, and the re-
lease of IL-8 was not affected, providing additional evidence
that specific PKC isoforms may be differentially involved in the
pathways leading to cytokine production. However, the fact
that the selective inhibitor of PKC- did not completely abro-
gate LPS-induced TNF- production may suggest that the
PKC- signaling pathway does not control TNF- production
exclusively.
Overall, this paper contributes to the understanding of the
complex process of aging of the immune system and identifies
a progressive decline in RACK-1 expression with aging, re-
lated to a decline in DHEA level. The identification of changes
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in the immune cells will allow the elaboration of better strat-
egies for the prevention of infective diseases in the elderly [53].
Even in the presence of intrinsic defects in peripheral lym-
phocytes of elderly subjects, it is possible that these may be
overcome by measures that are relatively easy in principle (i.e.,
to test whether hormonal treatment can restore immune func-
tions declined with aging); yet, these principles need to be
clearly tested in appropriate clinical protocols and settings
with particular caution because of the unresolved problems
related to the risk of cancer associated with this type of
treatment.
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